In parallel, adaptive T cell therapies such as IL13Rα2-targeted chimeric antigen receptor (CAR) T cells are also gaining attention owing to their effectiveness against tumor growth in glioma and other tumor models. Here, IL13RA2 is linked to neoplasm.